Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marianne Deroose"'
Autor:
Yun-Kyoung Lee, Bryan Diaz, Marianne Deroose, Samuel X. Lee, Sandro Belvedere, Domenico Accili, Rudolph L. Leibel, Hua V. Lin
Publikováno v:
Molecular Metabolism, Vol 49, Iss , Pp 101187- (2021)
Objective: Forkhead box protein O1 (FOXO1) plays a key role in regulating hepatic glucose production, but investigations of FOXO1 inhibition as a potential therapeutic approach have been hampered by a lack of selective chemical inhibitors. By profili
Externí odkaz:
https://doaj.org/article/638a5b8971d74b309029bffc59f3e20e
Autor:
Marianne Deroose, Amelie Forest, Thompson N. Doman, Veena Kandaswamy, Michael Kalos, Shengwu Liu, Ruslan D. Novosiadly, Ting Chen, Gerald Hall, Kwok-Kin Wong, David Surguladze, David Schaer, Yung-mae Yao
Publikováno v:
Cancer Research. 78:3632-3632
Necitumumab (EGFR inhibitor) in combination with chemotherapy provides a modest, yet a significant improvement in overall survival over chemotherapy alone in patients with advanced squamous non-small cell lung carcinoma (NSCLC). However, combination
Autor:
Nelusha Amaladas, Richard P. Beckmann, David Schaer, Carmine Carpenito, Lacey M. Litchfield, Michael Kalos, Kirk A. Staschke, Philip W. Iversen, Yanxia Li, Linda Chung, Ruslan D. Novosiadly, Ying Cindy Wang, Jack A. Dempsey, Alfonso De Dios, Andrew Capen, Marianne Deroose, Lysiane Huber, Trent R. Stewart, Erik R. Rasmussen, Sean Buchanan, Darin Chin, Amelie Forest, Xueqian Gong, Farhana F. Merzoug
Publikováno v:
Cancer Research. 78:4569-4569
The approval of abemaciclib and additional cyclin dependent kinases 4 & 6 (CDK4/6) inhibitors for the treatment of HR+ breast cancer has provided new therapeutic options to patients. As CDK4/6 inhibitors become part of the standard of care, combinati